Introduction
Invasive fungal infections (IFIs) represent a major cause of morbidity and mortality among patients with acute leukaemia who receive induction chemotherapy and among haematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) [1] . A retrospective study carried out among HSCT recipients in the period [2007] [2008] [2009] [2010] [2011] [2012] showed that the overall incidence of IFIs was 11.3%, and that the majority of these were due to Aspergillus spp. and/or to other moulds [2] .
Current guidelines recommend the use of posaconazole as primary prophylaxis for the prevention of IFIs in acute myeloid leukaemia (AML) and for patients undergoing HSCT with GVHD [3] . Posaconazole is a second-generation triazole agent, which is currently available in two oral formulations: a suspension and delayed-release tablets. The oral suspension has saturable absorption, that is improved by food or a high fat meal, and whose oral bioavailability may be decreased by the co-administration of gastric acidlowering agents [4, 5] . A highly variable pharmacokinetic profile of posaconazole oral suspension often leads to suboptimal concentrations of posaconazole with an attendant risk of breakthrough IFIs [6] .
A delayed-release tablet formulation was developed with the intention of overcoming some of the limitations of oral posaconazole suspension. Although the new formulation has a generally improved oral bioavailability, there are conflicting results in terms of posaconazole serum trough concentrations (C min ) observed in real-life following administration of the standard 300 mg once-daily dose. Some authors have documented better drug exposure [7] that is independent of the regimen, clinical status and/or comedications [8, 9] , whereas others showed that attainment of therapeutic concentrations may still be problematic [10, 11] . The variability of posaconazole exposure may be caused by erratic absorption as well as enhanced clearance (CL). Furthermore, posaconazole is very highly bound to plasma proteins and its elimination is mediated by the UDP-glucuronosyltransferase (UGT) 1A4 [12] . Accordingly, hypoalbuminaemia and/or the presence of factors that may upregulate the activity of UGT1A4 may lead to an increase of posaconazole CL. A recent case report suggested that in a patient with AML receiving posaconazole as delayed-release tablets, hypoalbuminaemia and hyperbilirubinaemia may have been responsible for an enhancement of posaconazole CL, leading to subtherapeutic concentrations [13] .
The aim of this single-centre retrospective study was to determine risk factors associated with subtherapeutic concentrations of posaconazole among adult patients with haematological malignancies who received posaconazole tablets for prophylaxis of IFIs.
Methods

Study design
This was a single-centre retrospective study that included adult patients with haematological malignancies who were admitted at the Clinic of Haematology, Santa Maria della Misericordia University Hospital of Udine, Italy in the period January 2016-December 2017. All patients received posaconazole delayed-release tablets for prophylaxis of IFIs after induction chemotherapy for acute leukaemia or GVHD complicating HSCT. Therapeutic drug monitoring (TDM) of posaconazole was performed on all patients. The study was approved by the Regional Ethics Committee. Written informed consent was waived due to the retrospective and observational nature of the investigation.
All the patients were recommended to take posaconazole tablets with food. Therapy was started with an initial loading dose of 300 mg every 12 h on Day 1 and continued in the subsequent days with a maintenance dose of 300 mg once daily until the first episode of TDM, which was performed at steady-state (after 4 or more days from treatment initiation). The target C min was >0.7 mg l À1 according to current recommendations for prophylaxis [14, 15] . In the presence of subtherapeutic C min (≤ 0.7 mg l À1 ), the maintenance dose was increased to 400 mg. Blood samples for determination of trough levels (C min ) were collected in the morning immediately prior to the scheduled intake of posaconazole tablets. Compliance was verified at each TDM instance and reported in the patient data sheet. Samples were immediately delivered to the Institute of Clinical Pharmacology, where they were centrifuged to obtain serum. The separated serum samples were stored at À20°C until analysed (once weekly on Tuesdays). Posaconazole concentrations were estimated using a previously described liquid chromatography-tandem mass spectrometry analytic method [16] . The intra-and inter-day coefficients of variation were 0.17-1.02% and 0.86-1.67%, respectively. The lower limit of quantitation was 0.04 mg l À1 and the limit of detection was 0.02 mg l À1 .
Data on demographic and clinical characteristics (age, weight, height, gender, underlying haematological disease, presence of acute or chronic GVHD, duration of posaconazole treatment), laboratory parameters (alanine aminotransferase, serum albumin, serum creatinine, serum bilirubin concentrations) and on all co-medications (with dosages) were retrieved for each patient at baseline and at each TDM episode. The following risk factors potentially affecting posaconazole absorption were collected for evaluation: use of proton pump inhibitors (PPIs), presence of mucositis and of diarrhoea [11] . Additionally, the following risk factors potentially affecting the CL of posaconazole were collected: presence of hypoalbuminaemia, presence of hyperbilirubinaemia [13] and use of intermediate or high dose steroids (defined as >0.7 mg kg À1 daily).
Statistical analysis
The Kolmogorov-Smirnov test was used to assess whether clinical data were normally distributed. The mean ± standard deviation, median and 25 th -75 th interquartile ranges (IQR)
were used for descriptive statistics. Intra-individual and inter-individual variability of posaconazole C min was assessed by calculating the median of the coefficient of variation (CV) of all the C min measured in a single patient and the CV of the average C min of each patient, respectively. Univariate and multivariate linear mixed-effect models (with a random effect for patient accounting for correlation amongst repeated measurements of the same subjects) were performed to identify the independent predictors of posaconazole C min . Multivariate stepwise backward analysis included all variables significant at P ≤ 0.200 in the univariate analysis. A Kruskal-Wallis test was used to compare continuous data among groups. Bonferroni correction for multiple comparisons was applied, as appropriate. A P-value <0.05 was required for statistical significance. All statistical analysis and plotting were performed using R version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [17] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [18, 19] .
Results
Sixty-six consecutive patients were included in the study. Patient demographics and clinical characteristics are summarized in Table 1 ( Figure 1 summarizes distributions of posaconazole C min in relation to the duration of treatment among the studied patients. Overall, a statistically significant progressive increase of posaconazole C min was observed in relation to the duration of treatment (P = 0.005). After correction for multiple comparisons, significant differences in median posaconazole C min were observed between week 1 and 4 (C min of 0.9 vs. 1.27 mg l À1 , P = 0.007) and week 1 and >4 (C min of 0.9 vs. 1.37 mg l À1 , P < 0.001).
Univariate and multivariate mixed-effect linear regression analysis of the clinical variables associated with posaconazole C min are reported in Table 2 . Multivariate analysis showed that in patients receiving posaconazole tablets, male gender, co-treatment with PPIs or with steroids was associated with a 28%, 45% or 44% reduction in C min . Conversely, time from starting therapy was associated with a minimal (0.03%) increase in C min in our patient population. The presence of AML, HSCT and mucositis of any grade were not found to be significantly associated with posaconazole exposure in our patient cohort. Figure 2 compares box and whisker plots of posaconazole C min between patients co-treated with PPIs (PPIs, n = 113 observations), those co-treated with intermediate or high dose steroids (steroids, n = 9 observations), those co-treated with PPIs plus intermediate or high dose steroids (PPI + steroids, n = 20 observations), and those who did not receive these co-treatments (controls, n = 34 observations). Median posaconazole C min was significantly lower among patients receiving these co-treatments (P < 0.001). Following post-hoc analysis, each group of co-treatment had significantly lower median C min than controls (PPIs + steroids vs. controls, 0.74 vs. 1.52 mg l À1 , P < 0.00; steroids vs. controls, 1.01 vs.
1.52 mg l À1 , P = 0.003; PPIs vs. controls, 1.10 vs. 1.52 mg l À1 , P < 0.001).
Discussion
The use of posaconazole is recommended for patients with haematological malignancies who receive induction chemotherapy or for HSCT recipients with GVHD requiring immunosuppression [3] . A target C min > 0.7 mg l À1 is advocated [15] . Approximately 50% of patients receiving standard dose of the oral suspension (200 mg every 8 h) achieve this target [15] . In contrast, higher rates of target attainment are observed with the use of the delayed-released tablet formulation (70-90%) [7, 20, 21] . Marked variability in posaconazole exposure is still observed in PK studies of the delayed-released tablet formulation [10, 11, [22] [23] [24] . Patients receiving 300 mg daily have a median posaconazole C min concentration of 1.08-1.89 mg l
À1
at steady state with a concentration range of <0.1-7.89 mg l À1 . Our data are consistent with these observations.
We observed a median C min 1.17 mg l À1 , with a range of 0.17- and intra-patient variability were 43.9% and 29.3%, respectively, similarly to those previously reported [22] . Furthermore, the proportion of subtherapeutic C min is comparable (17.0% in our study vs. 8.6%, 15.4% and 29% in other studies) [10, 23, 25] . Identification of clinical factors associated with posaconazole exposure is of great clinical concern, as posaconazole underexposure was associated with the occurrence of breakthrough IFIs both in experimental animal models [26] and in some clinical studies [5, 27] . Although the new delayed-release formulation seems to be less prone to suboptimal absorption, the pharmacokinetic variability of posaconazole may depend also on other factors that affect CL. Our study shows that the use of PPIs and/or the use of steroids at dosages ≥0.7 mg kg À1 daily are significant risk factors for drug underexposure. The effects of PPIs on intragastric pH is dose-dependent and is related to the relative potency of each drug [28] . It should be recognized that, differently from what we did in the current study, only a minority of the studies that previously assessed the influence of PPIs on posaconazole tablet exposure specified the type and dosage of the PPI. Different choices and/or different dosages of the PPIs may explain why only some of the real-world studies on posaconazole tablets still found co-administration of these drugs as being a risk factor of low posaconazole levels, similarly to us. A retrospective study conducted among 157 patients with haematological malignancies treated with posaconazole tablets showed that at multivariate analysis the use of PPIs (P = 0.015) was a risk factor for subtherapeutic posaconazole concentrations [11] . In that study, other risk factors were the presence of Box (median and 25th-75th percentiles) and whiskers (5th-95th percentiles) plot of posaconazole trough concentrations (C min ) following administration of posaconazole tablets in hematologic patients receiving no interacting co-treatments (Controls; 34 observations in 20 patients), in those receiving proton pump inhibitors (PPIs; 113 observations in 43 patients), in those receiving intermediate or high dose steroids (>0.7 mg kg À1 daily) (Steroids;
9 observations in 5 patients) and in those receiving proton pump inhibitors plus intermediate or high dose steroids (PPIs+ steroids; 20 observations in 13 patients). The dashed line identifies posaconazole target levels for prophylaxis (C min > 0.7 mg l À1 ) of fungal infections. A P-value < 0.001 was obtained at Kruskal-Wallis test. A significant difference after post-hoc Bonferroni correction was observed between Controls and PPIs (P < 0.001), Controls and Steroids (P = 0.003) and Controls and PPIs+ Steroids (P < 0.001) diarrhoea (P < 0.001), low baseline albumin concentrations (P = 0.011) and body weight > 90 kg (P = 0.047) [11] . Body weight and diarrhoea were significant risk factors for drug underexposure also in an earlier retrospective investigation [10] . Conversely, in a recent retrospective study carried out among 48 haematological malignancy patients who had 325 posaconazole C min measurements, no significant relationship between the use of PPIs and the risk of suboptimal exposure with posaconazole tablets was observed at multivariate analysis [25] . Similar findings were documented in another group of haematological patients [20] , in lung transplanted patients [29] and in healthy volunteers receiving a 400 mg daily dose [8] . The presence of gastro-intestinal mucositis is not associated with the risk of posaconazole underexposure during the use of delayed-release tablets in two previous studies [23, 24] . The most novel aspect of our analysis was the finding that corticosteroids may be a risk factor for low posaconazole exposure in patients with haematological malignancy. Posaconazole is metabolized by UGT1A4 [12] . Intermediate or high dose steroids may have upregulated the activity of this enzyme and resulted in increased CL. This assumption is based on previous studies showing that UGT1A4 may be upregulated by steroids (17β-estradiol) in pregnancy leading to an increased elimination of lamotrigine, which is a substrate for UGT1A4 [30] . UGT1A4 contains Pregnane-Xreceptor (PXR) response elements, which by acting as xenobiotic receptor for a wide range of compounds, including steroids, may induce the glucuronidation process [30, 31] . This hypothesis is supported by a retrospective analysis conducted among 52 haematologic patients by Chin et al. [23] . These authors found at multivariate analysis that patients not receiving treatment for GVHD [including also high-dose steroids (either ≥1 mg kg À1 daily for patients with acute GVHD or ≥0.8 mg kg À1 every other day for patients with chronic GVHD] had higher odds of achieving a therapeutic serum level than those receiving GVHD treatment (OR, 5.85; 95% CI, 1.09-31.5; P = 0.04) [23] . Indeed, we recognize that collinearity between steroids and HSCT might have prevented HSCT from being identified as an independent risk factor in our study, differently from what was observed by other authors [25] . Overall, our findings suggest that TDM of posaconazole tablet could be especially important for patients receiving both PPI and steroids.
We recognize that our study has several limitations. The retrospective nature and the limited sample size may limit the generalizability of the findings and further prospective studies are required to confirm the correlation with steroids, which only just reached significance. Nevertheless, our work suggests that posaconazole exposure during treatment with delayed-released tablet formulation may be affected by the use of PPIs and/or of steroids. A prospective clinical study is warranted to confirm our findings.
